1.北京中医药大学附属护国寺中医医院针灸科,北京 100034
2.北京中医药大学东方医院心内科,北京 100078
张晓羽,女,41岁,博士,副主任医师。研究方向:肿瘤心脏病学、心血管病的中西医结合治疗。
扫 描 看 全 文
张晓羽,赵海滨.芪参益气滴丸治疗抗肿瘤药物相关心功能不全的临床疗效观察[J].北京中医药,2023,42(2):156-161.
ZHANG Xiao-yu,ZHAO Hai-bin.Clinical observation of Qishen Yiqi Dropping Pills in the treatment of cancer therapeutics-related cardiac dysfunction[J]. Beijing Journal of Traditional Chinese Medicine,2023,42(02):156-161.
张晓羽,赵海滨.芪参益气滴丸治疗抗肿瘤药物相关心功能不全的临床疗效观察[J].北京中医药,2023,42(2):156-161. DOI: 10.16025/j.1674-1307.2023.02.008.
ZHANG Xiao-yu,ZHAO Hai-bin.Clinical observation of Qishen Yiqi Dropping Pills in the treatment of cancer therapeutics-related cardiac dysfunction[J]. Beijing Journal of Traditional Chinese Medicine,2023,42(02):156-161. DOI: 10.16025/j.1674-1307.2023.02.008.
目的,2,观察芪参益气滴丸治疗恶性肿瘤患者抗肿瘤药物相关心功能不全的临床疗效。,方法,2,选取2017年3月—2021年5月就诊于北京中医药大学附属护国寺中医医院的各种晚期恶性肿瘤合并心功能不全患者150例,采用随机数字表法分为观察组与对照组,各75例。对照组给予常规西药治疗;观察组在此基础上口服芪参益气滴丸,2组均以4周为1个疗程,连续治疗3个疗程。对比2组临床疗效及治疗前后6 min步行距离、血浆脑钠肽(BNP)、心率变异性(HRV)指标[全部窦性心搏RR间期的标准差(SDNN)、相邻RR间期差值的均方根(RMSSD)、RR间期平均值标准差(SDANN)、相邻NN之差>50 ms的个数占总窦性心搏个数的百分比(PNN50)]、心功能指标[左心室舒张末期容积(LVEDV)、左心室收缩末期容积(LVESV),并计算左心室射血分数(LVEF)]、心肌酶学指标[肌酸激酶同工酶(CK-MB)、乳酸脱氢酶(LDH)]及血清高敏C-反应蛋白(hs-CRP)、白细胞介素6(IL-6)、用药安全性。,结果,2,观察组治疗后总有效率91.0%,高于对照组的74.2%(,P,<,0.05);2组治疗后LVEDD、LVESD、CK-MB、LDH及BNP均较治疗前降低(,P,<,0.05),6 min步行距离、SDNN、SDANN、RMSDD、PNN50及LVEF均较治疗前升高(,P,<,0.05),且观察组治疗后6 min步行距离、BNP、HRV指标、心功能指标、血清hs-CRP、IL-6及心肌酶学指标改善情况均优于对照组(,P,<,0.05)。治疗期间2组均未发生药物相关不良反应。,结论,2,芪参益气滴丸配合西药治疗恶性肿瘤患者抗肿瘤药物相关心功能不全疗效优于单纯西药治疗,且安全性较高。
Objective,2,To investigate the therapeutic effect of Qishen Yiqi (QSYQ) Dropping Pills on cancer therapeutics-related cardiac dysfunction(CTRCD).,Methods,2,A total of 150 malignant tumor patients with CTRCD who visited Huguosi Hospital of Chinese Medicine, Beijing University of Chinese Medicine from March 2017 to May 2021 were selected, and according to random number table method,they were divided into control group and observation group,with 75 cases in each one.The control group was given conventional western medicine treatment,and the observation group was given QSYQ Dropping Pills on the basis of the control group.Both groups were treated for one course of 4 weeks,continuously for three courses.Clinical efficacy, 6-minute walking test,BNP, heart rate variability (HRV),including SDNN, RMSSD,SDANN,PNN50, cardiac function indicators including LVEDV, LVESV, myocardial enzymology indexes including CK-MB and LDH, Serum high sensitivity C- reactive protein (CRP), IL-6 and safety in 2 groups before and after treatment were observed and evaluated.,Results,2,The total effective rate of the treatment group was 91.0%, which was significantly higher than that of the control group,that was 74.2% (,P,<,0.05). 6-minute walking distance,SDNN,SDANN,RMSDD, PNN50 and LVEF were significantly increased after treatment(,P,<,0.05),The improvement of 6-minute walking distance, BNP, HRV, cardiac function, serum hs-CRP, IL-6 and myocardial enzymology in the observation group were better than those in the control group (,P,<,0.05). During the treatment,there was no drug-related adverse reaction in both groups(,P,>,0.05).,Conclusion,2,QSYQ Dropping Pills combined with conventional western medicine has better efficacy in the treatment of CTRCD than only western medicine treatment with high safety.
芪参益气滴丸抗肿瘤药物相关心功能不全炎性因子
Qishen Yiqi Dropping Pillscancer therapeutics-related cardiac dysfunctioninflammatory factor
国家卫生健康委员会疾病预防控制局,国家心血管病中心,中国医学科学院阜外医院,等.中国高血压健康管理规范(2019)[J].中华心血管病杂志,2020,48(1):10-46.
LEE L,CHEUNG WY,ATKINSON E,et al.Impact of comorbidity on chemotherapy use and outcomes in solid tumors:a systematic review[J].J Clin Oncol,2011,29(1):106-117.
COLEMAN MP. Cancer survival: global surveillance will stimulate health policy and improve equity[J]. Lancet, 2014,383(9916):564-573.
刘少烽, 莫思燕, 黄世香. 从肿瘤心脏病学探讨恶性肿瘤与心血管疾病及药物干预相关性研究进展[J]. 中国肿瘤临床,2019,46(21):1126-1129.
陈广文, 赵林. 抗肿瘤药物相关心功能不全的预防与治疗[J]. 中国医学科学院学报,2019,41(6):842-850.
刘斌亮,王延风,马飞.从肿瘤学出发,浅谈肿瘤心脏病学的发展、现状与挑战[J].中国心血管杂志,2018,23(5):357-359.
CURIGLIANO G, LENIHAN D, FRADLEY M, et al. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations[J]. Ann Oncol, 2020,31(2):171-190.
陈景瑞, 魏静, 朱利洁,等. 芪参益气滴丸对心血管系统疾病的药理作用研究进展[J]. 时珍国医国药,2015,26(2):434-437.
PLANA JC, GALDERISI M, BARACA, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging[J]. Eur Heart J Cardiovasc Imaging, 2014,15(10):1063-1093.
张楠, 王敬然, 赵亚红,等. 丹红注射液对恶性肿瘤患者氟尿嘧啶所致心脏毒性的保护作用研究[J]. 实用心脑肺血管病杂志,2018,26(7):86-89.
李星星, 林泉, 逯金金,等. 加用芪参桃红颗粒对慢性心力衰竭疗效的影响观察[J]. 北京中医药,2022,41(4):374-378.
许绍信, 刘劲松, 陶延丽. 芪参益气滴丸联合曲美他嗪对老年慢性心力衰竭病人心率变异性及心功能的影响[J]. 中西医结合心脑血管病杂志,2020,18(21):3616-3619.
中华医学会心血管病学分会心力衰竭学组,中国医师协会心力衰竭专业委员会,中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南(2018)[J].中华心血管病杂志,2018,46(10): 760-789.
郑筱萸.中药新药临床研究指导原则[M].北京:中国医药科技出版社,2002:233-237.
任东晓, 张本华. 常见抗肿瘤药心脏毒性研究进展[J]. 中华老年多器官疾病杂志,2019,18(7):548-551.
周末, 任景怡. 肿瘤药物治疗相关的心力衰竭:临床特点、监测及管理[J]. 中国心血管杂志,2018,23(5):366-370.
吕海辰, 夏云龙. 发展中的肿瘤心脏病学[J]. 中国医刊,2019,54(8):816-819.
李田宏, 谢晓冬. 抗肿瘤药物心脏毒性的中医药防治进展[J]. 中国肿瘤临床与康复,2019,26(4):510-512.
邱志凌, 朱宝琛, 李琪琳. 中医药防治心力衰竭的现状研究[J]. 北京中医药,2021,40(6):566-570.
刘薇, 张玉焕, 李争. 芪参益气滴丸对老年气虚血瘀型心力衰竭患者心肌保护、炎症状态的影响[J]. 陕西中医,2021,42(1):37-40.
戴顺妮. 芪参益气滴丸联合参麦注射液对慢性心力衰竭患者汗出症状、心功能及BNP的影响[J]. 现代中西医结合杂志,2020,29(15):1675-1679.
TANG DX, ZHAO HP, PAN CS, et al.QiShenYiQi Pills, a compound Chinese medicine, ameliorates doxorubicin-induced myocardial structure damage and cardiac dysfunction in rats[J]. Evid Based Complement Alternat Med, 2013,2013:480597.
TONG JY,XU YJ,BIAN YP,et al.Effect and mechanism of Qishen Yiqi Pills on adriamycin-induced cardiomyopathy in mice[J].Chin J Nat Med, 2013,11(5):514-518.
关旭敏, 刘基巍, 夏云龙. 2019 AHA肿瘤心脏病学之血管和代谢观点科学声明解读[J]. 中国循环杂志,2019,34(z1):101-107.
刘彤, 夏云龙. 抗肿瘤治疗与心房颤动[J]. 实用心电学杂志,2019,28(6):397-401,428.
陈林,刘琼,荆志伟,等.中医药治疗缺血性心肌病临床研究进展[J].北京中医药,2022,41(2):213-217.
0
浏览量
0
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构